In Vitro & In Vivo Diagnostic Substances
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 32.62M | $303.0M | 14.99% | +112.0K | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 12.83M | $119.0M | 5.90% | -- | 2026-03-31 |
| T. Rowe Price Investment Management, Inc. | 10.16M | $94.0M | 4.67% | +8.96M | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.57M | $88.0M | 4.39% | -- | 2026-03-31 |
| DIMENSIONAL FUND ADVISORS LP | 9.13M | $84.0M | 4.20% | +1.73M | 2026-03-31 |
| STATE STREET CORP | 8.59M | $79.0M | 3.95% | -134.5K | 2026-03-31 |
| MACKENZIE FINANCIAL CORP | 7.80M | $72.0M | 3.58% | -95.2K | 2026-03-31 |
| NEUBERGER BERMAN GROUP LLC | 7.75M | $71.0M | 3.56% | +6.55M | 2026-03-31 |
| Hudson Bay Capital Management LP | 6.50M | $60.0M | 2.99% | +180 | 2026-03-31 |
| SG Americas Securities, LLC | 6.27M | $58.0M | 2.88% | +4.65M | 2026-03-31 |
